About this episode
Jonathan Faison runs the ROTY Biotech Community . Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics (0:30). Data risk for Ogsiveo and Mirdametinib (5:50). This is an excerpt from a recent episode . Show Notes: Biotech's Hidden Gems: Smart Strategies For A Challenging Market SpringWorks Therapeutics Q3 2024 Earnings Call Transcript Read the transcripts For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions